<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00374647</url>
  </required_header>
  <id_info>
    <org_study_id>STN INV INT</org_study_id>
    <nct_id>NCT00374647</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of Early Calcineurin Inhibitor Withdrawal in Primary Renal Allografts</brief_title>
  <official_title>Open Label Randomized Single Study to Evaluate the Safety &amp; Efficacy of Early CNI Withdrawal in Recipients of Primary Renal Allografts Maintained Long-Term on Mycophenolate Mofetil; MMF (CellCept) and Sirolimus (Rapamune)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety and efficacy of early corticosteroid withdrawal and simultaneous
      calcineurin inhibitor withdrawal in recipients of primary renal allografts maintained
      long-term on MMF and sirolimus.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite endpoint of either acute rejection, biopsy proven calcineurin inhibitor toxicity, or failure of the estimated BSA indexed GFR by MDRD method to improve by 20% from time randomization to 12 months.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal allograft function at 6 and 12 months.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of biopsy proven acute rejection at 6 and 12 months.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first rejection.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total number of rejection episodes per patient.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft loss and patient death.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment failure.</measure>
  </secondary_outcome>
  <enrollment type="Actual">17</enrollment>
  <condition>Primary Renal Allograft</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients between 18 and 75 years of age.

          -  Patients who are 90 to 240 days after having received a primary living or cadaver
             renal allograft.

          -  Patients maintained on a regimen of cyclosporine or tacrolimus and MMF since
             transplantation.

          -  Capable of providing written informed consent.

          -  No known contraindications to treatment with sirolimus.

        Exclusion Criteria:

          -  Pregnant or lactating.

          -  Acute rejection within 90 days prior to study randomization.

          -  More than one biopsy proven acute rejection episode prior to study randomization.

          -  Previously received or are receiving an organ transplant other than kidney.

          -  Receiving sirolimus prior to entry.

          -  Severe diarrhea or other gastrointestinal disorders that may interfere with their
             ability to absorb oral medication.

          -  Evidence of active systemic infection requiring antibiotics, or HIV, HCV, HBV
             infection.

          -  History of malignancy in the past 5 years.

          -  Require dialysis at the time of study entry.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Woodle, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2006</study_first_submitted>
  <study_first_submitted_qc>September 8, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2006</study_first_posted>
  <last_update_submitted>June 5, 2008</last_update_submitted>
  <last_update_submitted_qc>June 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>E. Steve Woodle, MD, FACS</name_title>
    <organization>University of Cincinnati</organization>
  </responsible_party>
  <keyword>Renal</keyword>
  <keyword>Kidney</keyword>
  <keyword>Transplant</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

